nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert
A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target
and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Machine learning algorithm reveals long-theorized glass phase in crystal
Scientists have found evidence of an elusive, glassy phase of matter that emerges when a crystal’s perfect internal pattern is disrupted. X-ray technology and machine learning converge to shed light…
Mapping plant functional diversity from space
HKU ecologists revolutionize ecosystem monitoring with novel field-satellite integration. An international team of researchers, led by Professor Jin WU from the School of Biological Sciences at The University of Hong…
Inverters with constant full load capability
…enable an increase in the performance of electric drives. Overheating components significantly limit the performance of drivetrains in electric vehicles. Inverters in particular are subject to a high thermal load,…